Parkinson's disease and gut microbiota metabolites: The dual impact of vitamins and functional amyloids

IF 4.2 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochimica et biophysica acta. Molecular basis of disease Pub Date : 2025-04-18 DOI:10.1016/j.bbadis.2025.167862

Fatemeh Mirab , Mitra Pirhaghi , Daniel E. Otzen , Ali Akbar Saboury

引用次数: 0

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the abnormal accumulation of alpha-synuclein (α-Syn). Recent research emphasizes the significant role of the gut microbiota, the diverse community of microbes living in the intestines, in modulating α-Syn pathology. This review explores the bi-directional communication along the microbiota-gut-brain axis, highlighting the paradoxical impact of two gut microbiota metabolites—functional bacterial amyloids (FuBA) and vitamins—on neurodegenerative diseases, particularly PD. FuBA contributes to PD pathogenesis by promoting α-Syn aggregation, while vitamins offer neuroprotection through their anti-amyloidogenic, antioxidant, and anti-inflammatory properties. Understanding these processes could lead to precision clinical approaches and novel strategies for managing and preventing PD.

Abstract Image

查看原文本刊更多论文

帕金森病和肠道微生物代谢物：维生素和功能性淀粉样蛋白的双重影响

帕金森病（PD）是一种以α-突触核蛋白（α-Syn）异常积累为特征的神经退行性疾病。最近的研究强调了肠道微生物群在调节α-Syn病理中的重要作用，肠道微生物群是生活在肠道中的多种微生物群落。这篇综述探讨了沿着微生物-肠-脑轴的双向交流，强调了两种肠道微生物代谢物-功能性细菌淀粉样蛋白（FuBA）和维生素-对神经退行性疾病，特别是PD的矛盾影响。富ba通过促进α-Syn聚集参与PD的发病机制，而维生素通过其抗淀粉样变性、抗氧化和抗炎特性提供神经保护。了解这些过程可以导致精确的临床方法和管理和预防PD的新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochimica et biophysica acta. Molecular basis of disease 生物-生化与分子生物学

CiteScore

12.30

自引率

0.00%

发文量

218

审稿时长

32 days

期刊介绍： BBA Molecular Basis of Disease addresses the biochemistry and molecular genetics of disease processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The submission of uninvited reviews to BBA - Molecular Basis of Disease is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.